Last reviewed · How we verify

NCT05965752

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

Completed NA Results posted Last updated 18 July 2025
What this trial tests

NA trial testing BrainHQ/Active Comparator Activity in Long COVID in 328 participants. Completed in 10 June 2024.

Timeline
1 September 2023
Primary endpoint
10 June 2024
10 June 2024

Quick facts

Lead sponsorDuke University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment328
Start date1 September 2023
Primary completion10 June 2024
Estimated completion10 June 2024
Sites24 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

18 and older, any sex, with Long COVID or Long COVID-19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Total Number of Participants Enrolled in Each Appendix Primary · 160 Days

Appendix-specific outcome measure data will be reported under the associated NCT ID.

GroupValue95% CI
BrainHQ Active Comparator64
BrainHQ67
BrainHQ + PASC CoRE66
Brain HQ + tDCS-active66
Brain HQ + tDCS-sham65

Sponsor's own description

This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Long COVID: Long-Term Impact of SARS-CoV2.
    Makhluf H, Madany H, Kim K. · · 2024 · cited 19× · PMID 38611624 · DOI 10.3390/diagnostics14070711

Verify or expand the search:

Other trials of BrainHQ/Active Comparator Activity

Trials testing the same drug.

Other recruiting trials for Long COVID

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05965752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing